AWA
CRSP icon

Arete Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Arete Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,370
Closed -$478K – 444
2025
Q3 		$478K Buy
7,370
+1,642
+29% +$94.3K 0.03% 459
2025
Q2 		$279K Buy
+5,728
New +$222K 0.02% 585
2024
Q4 		– Sell
-10,376
Closed -$486K – 757
2024
Q3 		$486K Sell
10,376
-388
-4% -$19.7K 0.04% 383
2024
Q2 		$578K Sell
10,764
-133
-1% -$7.69K 0.05% 353
2024
Q1 		$743K Sell
10,897
-115
-1% -$8.23K 0.07% 251
2023
Q4 		$689K Sell
11,012
-589
-5% -$32.6K 0.05% 325
2023
Q3 		$527K Buy
11,601
+870
+8% +$44.9K 0.09% 227
2023
Q2 		$602K Sell
10,731
-283
-3% -$16.1K 0.05% 325
2023
Q1 		$498K Buy
11,014
+5,353
+95% +$260K 0.04% 343
2022
Q4 		$230K Sell
5,661
-2,160
-28% -$115K 0.02% 526
2022
Q3 		$511K Buy
7,821
+1,153
+17% +$83.6K 0.05% 294
2022
Q2 		$405K Buy
+6,668
New +$392K 0.04% 282
2021
Q4 		– Sell
-2,506
Closed -$277K – 506
2021
Q3 		$277K Buy
2,506
+54
+2% +$6.78K 0.03% 340
2021
Q2 		$303K Buy
+2,452
New +$298K 0.04% 263
2021
Q1 		– Sell
-1,598
Closed -$250K – 424
2020
Q4 		$250K Buy
+1,598
New +$189K 0.04% 341

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arete Wealth Advisors's CRSP Position: Q4 2025 in Review

Arete Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 7,370 shares — an estimated $478K sold.

Arete Wealth Advisors first reported a position in CRSP in Q4 2020 and held it in 15 quarters. The position peaked at $743K in Q1 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Arete Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arete Wealth Advisors sold 7,370 CRISPR Therapeutics shares in Q4 2025, an estimated $478K.
  • Arete Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 15 quarters.
  • Arete Wealth Advisors's CRISPR Therapeutics position peaked at $743K in Q1 2024.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Arete Wealth Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.